[Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
Yoshida
Haruhiko
H
Department of Gastroenterology, University of Tokyo Graduate School of Medicine.
Tateishi
Ryosuke
R
Omata
Masao
M
D000328:Adult; D000367:Age Factors; D000368:Aged; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D005260:Female; D005355:Fibrosis; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000191:economics* / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D012306:Risk; D015996:Survival Rate
D000998:Antiviral Agents; D007372:Interferons